๐๏ธ Verified NIH Record โข Updated 2026-04-29
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD (NCT06068075)
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study
๐ต Active, Not Recruiting Observational / Diagnostic ๐ Clinical Research Protocol Sponsor: Dana-Farber Cancer Institute
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
Who can join: Review the eligibility criteria below.
Location: Childrens Hospital Los Angeles โ Los Angeles, California
Age range: 12 Months to 50 Years
๐งช Interventions in This Study
- FoundationOne Liquid CDx (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (15 Sites)
- Childrens Hospital Los Angeles โ Los Angeles, California
- Children's Healthcare of Atlanta โ Atlanta, Georgia
- Massachusetts General Hospital Cancer Center โ Boston, Massachusetts
- Boston Children's Hospital โ Boston, Massachusetts
- Brigham and Women's Hospital โ Boston, Massachusetts
- Dana Farber Cancer Institute โ Boston, Massachusetts
- Children's Hospital's and Clinics of Minnesota โ Minneapolis, Minnesota
- Cincinnati Children's Hospital Medical Center โ Cincinnati, Ohio
- Nationwide Children's Hospital โ Columbus, Ohio
- Children's Hospital of Philadelphia โ Philadelphia, Pennsylvania
- Lifespan / Rhode Island Hospital โ Providence, Rhode Island
- St. Jude Children's Research Hospital โ Memphis, Tennessee
- UT Southwestern Medical Center โ Dallas, Texas
- University of Utah Childrens Medical Center โ Salt Lake City, Utah
- Seattle Children's Hospital โ Seattle, Washington
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ewing Sarcoma
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors โ Birmingham, Alabama
- RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT โ Houston, Texas
- EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT โ Cleveland, Ohio
- Lurbinectedin in FET-Fused Tumors โ Los Angeles, California
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas โ Scottsdale, Arizona
Explore by condition: All Ewing Sarcoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.